To date, no TLR3 agonists have reached market approval in the treatment of cancer due to systemic toxicity [25], limited efficacy [6], lack of structural homogeneity [26, 27], and most importantly lack of TLR3 specificity. This evidence concerns the gene TLR3 and cancer.